- Global Pharma News & Resources

Faron announces R&D Day to be held in June

TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, today announces plans to host a virtual R&D Day via webcast on Tuesday, 16 June 2020 at 3pm EEST, 1pm BST, 8am EDT.

The event will provide an opportunity for the Company’s management team to present its R&D strategy and provide insight into Faron’s two clinical stage programmes. Management will discuss the Company’s wholly-owned novel precision cancer immunotherapy, Clevegen, targeting Clever-1 positive tumour associated macrophages (TAMs) in selected metastatic or inoperable solid tumours, currently under development in the ongoing phase I/II MATINS clinical trial. Management will also discuss Traumakine, for the treatment of patients with Acute Respiratory Distress Syndrome (ARDS), which is currently being investigated in COVID-19 patients in the ongoing REMAP-CAP trial and the WHO’s Solidarity trial. There will be an opportunity to ask questions during the webcast.

For further information on the R&D Day, or to register for the event, please contact Consilium Strategic Communications at or telephone +44 (0)20 3709 5700.

For more information please contact:

Faron Pharmaceuticals Oy

Dr Markku Jalkanen, Chief Executive Officer


Editor Details

  • Company:
    • Faron Pharmaceuticals
  • Name:
    • Faron Pharmaceuticals
Last Updated: 28-May-2020